Study #2021-0509
A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel alone in participants with Advanced NonSmall Cell Lung Cancer who have progressed on prior Anti-PD-(L)1 Therapy and Chemotherapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Mehmet Altan
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.